Active clinical trials for "Schizophrenia"

The primary objective of this NIS is to assess the clinical benefit subjects derive from taking seroquel XR, using the CGI-CB. The secondary objective is to assess the effectiveness,safety and tolerability of seroquel XR tablets.

This study will determine whether eszopiclone will normalize sleep patterns and restore sleep-dependent enhancement of motor skill learning in patients with schizophrenia. The investigators will compare subjects taking a placebo to those taking 3 mg of eszopiclone with regard to: sleep architecture and sleep latency as measured by actigraphy and polysomnography and sleep-dependent motor skill learning.

The purpose of this research study is to gather information on the safety and efficacy of risperidone when used in routine clinical practice.

The purpose of this study is to examine behavioral and functional brain changes occuring as a result of cognitive remediation training in patients with schizophrenia. Extension and specificity of related changes will also be examined.

To determine whether ziprasidone provides good efficacy and tolerability in the treatment of schizophrenic Greek patients.

This is a study designed to identify genetic polymorphisms (also called allelic variants or genetic markers) that are associated with response to clozapine. This information will be used to enhance the understanding of clozapine response and side effects. DNA from patients will be examined for significant associations between allelic variants in candidate genes in relation to clozapine effects on positive and negative symptoms, global response, quality of life, relapse rates and side effects.

The purpose of this study is to evaluate epidemiological characteristics of patients that experience relapse and need an admission in psychiatric acute units across Spain.

We propose to study 900 sib-pairs with the disorder. Our Specific Aims are: 1) To clinical assess a pedigree sample having adequate power to detect genes for schizophrenia. 2) To conduct a genome scan to find such loci. 3) To transmit all data to the NIMH designated cell repository and data management centers. We will attain these goals by achieving the following: 1) From Taiwan and China, we will collect 900 Han Chinese sib-pairs having DSM-IV schizophrenia. 2) We will examine all family members using the Diagnostic Interview for Genetic Study and the Family Interviews for Genetic Study. The PI participated in the development and field testing of these interviews and has an already established training program for their use. They have been translated into Mandarin by the Taiwanese investigators, who have used them in prior studies. 3) Blood samples will be sent to the NIMH designated cell repository for creation of lymphoblastoid cell lines. 4) Clinical Data will be entered using the database software created for the NIMH Human Genetics Initiative. Data will be vetted and sent to the NIMH designated data management center. 5) We will complete a genome scan using 450 markers spaced at an average of 10 cM intervals using markers that have been optimized for use in the Han Chinese population. The scan will be completed with no cost to the NIMH through an agreement with Millennim Pharmaceuticals, a biotechnogy company in the the Boston area that the PI has worked with on a prior genetic linkage study of schizophrenia. All genetic analyses will be approved by our consultant, Eric Lander, PhD. 6) All clinical data will be made available to the scientific community by the end of the funding period. All genotypes wil be available one year after they are created but no later than a year after the funding period. This project as feasible because 1) The PI has already coordinated one multi-site genetic linkage study of schizophrenia and has participated in a second. 2) We have a long-standing relationship with our Taiwanese collaborators and an effective, albeit, more recent working relationship with our Chinese collaborators. 3) We have conservatively estimated that each site has access to more than enough available families having two schizophrenic siblings. 4) The PI's Harvard team has had prior experience collaborating on genotyping and linkage analysis projects with Millennium Pharmaceuticals. This, and Millennium's prior genotyping experience shows that the genotyping phase of the work is feasible.

The purpose of this study is to examine treatment practices of adult schizophrenia patients by their own doctors, and to assess patient outcomes when treated with long-acting risperidone injection over a two-year period of observation.

This study will create a DNA collection with blood samples from families with at least two siblings who have schizophrenia symptoms. This collection will help scientists identify genes that predispose people to schizophrenia.